Biopsy-driven study to identify biomarkers predictive of clinical response to second-line regorafenib in patients with metastatic colorectal cancer

Authors :: Adrian Gologan
Caroline Rousseau
Gerald Batist
Francine Aubin
Cyrla Hoffert
Adrian Langleben
Petr Kavan
Robert Zakarian
Source :: Journal of Clinical Oncology. 32:TPS3656-TPS3656
Publication Year :: 2014
Publisher :: American Society of Clinical Oncology (ASCO), 2014.
Abstract: TPS3656 Background: Biopsy-driven trials offer unique opportunities for discovery and validation of molecular signatures. We began a Phase II investigator-initiated study (IIS) to identify biomarke...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Pathology
medicine.diagnostic_test
business.industry
Colorectal cancer
medicine.disease
chemistry.chemical_compound
Second line
chemistry
Internal medicine
Regorafenib
Biopsy
medicine
In patient
business

Full Text Access

Tools